Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-302
2018-002894-23Phase 3Unknown
- Sponsor
- Incyte
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cholangiocarcinoma (CCA) comparing Pemigatinib with Gemcitabine + Cisplatin (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
pemigatinibgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2018-002894-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002894-23.